Saturday August 19th 2017

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

Source article:  

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Leave a Comment

More from category

Researchers Co-funded by National MS Society Report on New Way to Translate Lab Findings Aimed at Re
Researchers Co-funded by National MS Society Report on New Way to Translate Lab Findings Aimed at Re

/About-the-Society/News/Researchers-Co-funded-by-National-MS-Society-Repor [Read More]

Investigators Recruiting for Study of ALKS 8700 vs. Dimethyl Fumarate in Relapsing-Remitting MS
Investigators Recruiting for Study of ALKS 8700 vs. Dimethyl Fumarate in Relapsing-Remitting MS

/About-the-Society/News/Investigators-Recruiting-for-Study-of-ALKS-8700-vs [Read More]

Statement on House Oversight and Government Reform Committee Action on the Pricing Strategies for MS
Statement on House Oversight and Government Reform Committee Action on the Pricing Strategies for MS

/About-the-Society/News/Statement-on-House-Oversight-and-Government-Reform [Read More]

Drug blocked by regulators found to improve quality of life for MS patients
Drug blocked by regulators found to improve quality of life for MS patients

A drug that is blocked by the EU regulatory system has now been found to improve the quality of life of people with [Read More]

House Dems launch MS drug pricing probe
House Dems launch MS drug pricing probe

Democrats from the House Committee on Oversight and Government Reform have sent letters to seven drugmakers as part of [Read More]